Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GNTA | US
-0.03
-3.95%
Healthcare
Biotechnology
31/12/2023
13/04/2026
0.64
0.65
0.67
0.63
Genenta Science S.p.A. a clinical-stage biotechnology company engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. In addition it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan Italy.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
83.6%1 month
114.1%3 months
108.3%6 months
181.4%-
-
4.52
0.00
0.00
-11.48
-
-
-11.69M
11.71M
11.71M
-
-
-
-
-45.16
0.64
0.04
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.15
Range1M
0.32
Range3M
1.11
Rel. volume
0.61
Price X volume
46.77K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| HOOKIPA Pharma Inc | HOOK | Biotechnology | 1.15 | 11.38M | 1.77% | n/a | 5.69% |
| CytoMed Therapeutics Limited Ordinary Shares | GDTC | Biotechnology | 0.9651 | 11.14M | -3.49% | n/a | 3.98% |
| GeoVax Labs Inc | GOVX | Biotechnology | 1.28 | 10.91M | 4.07% | n/a | -6.03% |
| Adial Pharmaceuticals Inc | ADIL | Biotechnology | 1.57 | 10.06M | 0.00% | n/a | 0.00% |
| InMed Pharmaceuticals Inc | INM | Biotechnology | 0.7126 | 9.51M | -0.42% | n/a | 7.00% |
| VYNE Therapeutics Inc | VYNE | Biotechnology | 0.6248 | 9.22M | 2.43% | 1.29 | 0.19% |
| NovaBay Pharmaceuticals Inc | NBY | Biotechnology | 1.64 | 8.01M | 2.50% | n/a | -325.77% |
| Moleculin Biotech Inc | MBRX | Biotechnology | 2.72 | 7.74M | 3.82% | n/a | 3.00% |
| Ensysce Biosciences Inc | ENSC | Biotechnology | 0.5512 | 7.65M | 18.67% | n/a | 24.79% |
| Zivo Bioscience Inc | ZIVO | Biotechnology | 2.2 | 7.61M | -8.33% | n/a | -25.20% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.48 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.52 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 108.26 | 72.80 | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 11.71M | 3.66B | Emerging |